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Background: Although sophisticated methodologies are available, the use of endpoint polymerase chain reaction
(PCR) to detect 16S rDNA genes remains a good approach for estimating the incidence and prevalence of specific
infections and for monitoring infections. Considering the importance of the early diagnosis of sexually transmitted
infections (STIs), the development of a sensitive and affordable method for identifying pathogens in clinical samples
is needed. Highly specific and efficient primers for a multiplex polymerase chain reaction (m-PCR) system were
designed in silico to detect the 16S rDNA genes of four bacteria that cause genital infections, and the PCR method
was developed.
Methods: The Genosensor Probe Designer (GPD) (version 1.0a) software was initially used to design highly specific
and efficient primers for in-house m-PCR. Single-locus PCR reactions were performed and standardised, and then
primers for each locus in turn were added individually in subsequent amplifications until m-PCR was achieved.
Amplicons of the expected size were obtained from each of the four bacterial gene fragments. Finally, the analytical
specificity and limits of detection were tested.
Results: Because they did not amplify any product from non-STI tested species, the primers were specific. The
detection limits for the Chlamydia trachomatis, Neisseria gonorrhoeae, Mycoplasma hominis and Ureaplasma
urealyticum primer sets were 5.12 × 105, 3.9 × 103, 61.19 × 106 and 6.37 × 105 copies of a DNA template,
respectively.
Conclusions: The methodology designed and standardised here could be applied satisfactorily for the
simultaneous or individual detection of Chlamydia trachomatis, Neisseria gonorrhoeae, Mycoplasma hominis and
Ureaplasma urealyticum. This method is at least as efficient as other previously described methods; however,
this method is more affordable for low-income countries.
Keywords: Multiplex PCR, Cervicitis, Detection, 16S rDNA genes* Correspondence: lupita_aguilera@hotmail.com
1Medical bacteriology, Department of Microbiology, Escuela Nacional de
Ciencias Biológicas of Instituto Politécnico Nacional (ENCB-IPN), Esq. Prol.
Carpio y Plan de Ayala s/n Col. Santo Tomás, Del. Miguel Hidalgo CP 11340,
Mexico DF
Full list of author information is available at the end of the article
© 2014 Aguilera-Arreola et al.; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the
Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use,
distribution, and reproduction in any medium, provided the original work is properly credited. The Creative Commons Public
Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this
article, unless otherwise stated.
Aguilera-Arreola et al. BMC Research Notes 2014, 7:433 Page 2 of 7
http://www.biomedcentral.com/1756-0500/7/433Background
Cervicitis is an inflammatory condition of the cervix.
This condition is typically the consequence of an infec-
tion with a sexually acquired pathogen, most commonly
Chlamydia trachomatis and/or Neisseria gonorrhoeae.
Cervicitis is a frequent cause of dyspareunia, abnormal
mucopurulent discharge, friability and menstrual cycle
disorders [1,2]. However, asymptomatic rates are as high
as 30-45% in some populations [2]. The major concerns
regarding undiagnosed or incorrectly diagnosed asymp-
tomatic patients are reproductive sequelae or complica-
tions in the upper genital tract [2]. Until an efficacious
vaccine is developed, screening and treatment programs
appear to be the best method for disease prevention of
the “silent epidemic” of C. trachomatis [3]. Gonorrhoea,
which is caused by N. gonorrhoeae, is a common sexually
transmitted infection (STI) that is associated with high
morbidity and significant socioeconomic consequences.
N. gonorrhoeae has repeatedly demonstrated the ability to
develop resistance to all antimicrobial drugs introduced
as first-line therapy [4]. Surveillance of both of these
infectious diseases is critical for an accurate estimation
of disease incidence and for appropriate prevention and
treatment [5].
Mycoplasma and Ureaplasma species are commonly
found in the female genital tract. Although there is an on-
going debate, evidence that these microbes cause lower
genital tract diseases, including cervicitis, in women is
accumulating. Since Ureaplasma urealyticum has been
divided into U. urealyticum and U. parvum, the roles of
these species in causing urethritis and cervicitis have
become even less clear [6]. The accurate diagnosis of
Ureaplasma spp. and Mycoplasma hominis in cervical
samples is important because these microorganisms could
be pathogenic and could be associated with adverse preg-
nancy outcomes, postpartum sepsis, neonatal systemic in-
flammatory response syndrome and bronchopulmonary
dysplasia [1].
Diagnosis by nucleic acid amplification tests (NAATs)
is available for routine clinical use and is the preferred
and recommended method for detecting C. trachomatis
and N. gonorrhoeae infections. The higher sensitivity of
these tests is their main advantage over tissue culture and
other non-culture-based tests (e.g., enzyme immunoassay,
DNA probes) [7]. At present, fully and semi-automated
NAATs are commercially available. One disadvantage of
this method is the higher cost [7]. However, in high-
income countries, the increased test sensitivity might
make NAATs more cost-effective than other tests because
the use of NAATs might decrease the prevalence of these
genital infections [8]. However, in low-income countries,
the start-up cost of introducing commercial NAATs might
be prohibitive. Therefore, there is an urgent need for
improved and cost-effective diagnostic tests that wouldreduce the burden of STIs and allow for the creation
of mass screening programs to avoid the spread of these
diseases.
Data regarding the relative frequencies of these micro-
organisms in the Mexican population are minimal [9-11]
Moreover, infections caused by Chlamydia, Mycoplasma
and Ureaplasma species have not been adequately studied
in developing countries, and their prevalence is under-
researched. Considering the effect that infection or colon-
isation by C. trachomatis, N. gonorrhoeae, M. hominis and
Ureaplasma spp. might have on the female reproductive
tract and the high number of unrecognised infected indi-
viduals, who might serve as reservoirs for spreading infec-
tions to men and other women, there is an urgent need
for early and accurate diagnosis [1].
In the present study, highly specific and efficient primers
for the in-house multiplex polymerase chain reaction
(m-PCR) detection of C. trachomatis, N. gonorrhoeae,
M. hominis and U. urealyticum were bioinformatically
designed based on specific and conserved genetic se-
quences; these primers and the method were then stan-
dardised in the laboratory to rapidly, inexpensively and
effectively detect the four bacteria commonly associated
with cervicitis in a single reaction (quadruple/qx-PCR).
Methods
Biological materials
C. trachomatis ATCC® VR-878D™ DNA,M. hominis ATCC®
23114D™ DNA and DNA from cultures of U. urealyticum
ATCC® 27618™ and N. gonorrhoeae ATCC® 53420™
were used for the in vitro standardisation assays. U. urea-
lyticum DNA was obtained using the NucliSens® system
(bioMérieux, Marcy l’Etoile, France), and N. gonorrhoeae
DNA was obtained using the InstaGene™ matrix (Bio-Rad
Laboratories, Inc., Hercules, CA, US) according to the
manufacturer’s instructions. Streptococcus agalactiae ENCB
580 M16 and Staphylococcus saprophyticus ENCB, Lacto-
bacillus acidophilus ATCC® 9224™ and Gardnerella
vaginalis ATCC® 14018™ strains were grown overnight on
blood-based agar (Bioxon, Becton, Dickinson and Company,
México), MRS agar and Casman agar plates, respectively,
at 37°C. L. acidophilus ATCC® 9224™ and G. vaginalis
ATCC® 14018™ were incubated in an atmosphere of 5%
CO2. Two hundred thirty-seven cervicovaginal exudates
were collected with approval from the ethics committee
of the National Medical Centre November 20 (Centro
Médico Nacional 20 de Noviembre) approval number
02/09 at the Institute of Security and Social Services for
State Workers (Instituto de Seguridad y Servicios Sociales
de los Trabajadores del Estado, ISSSTE), Mexico City.
Written informed consent was obtained from all of the
study participants. All of the clinical specimens were
analysed by routine microbiological methods (data not
shown), and the clinical specimens that were negative
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the analytical specificity determinations (see below).
Primer design
The Genosensor Probe Designer (GPD) (version 1.0a)
software [12] was initially used to evaluate critical primer
parameters, including the melting temperature (Tm), dif-
ference in melting temperatures for primer pairs (ΔTm),
GC content (GC%), self-complementarity, repetitive se-
quences and Gibbs free energy. Primers with acceptable
physicochemical parameters were selected and aligned
with the sequence from the National Center for Biotech-
nology Information (NCBI) database using the Basic Local
Alignment Search Tool (BLAST) to test for possible
nonspecific interactions. Some primers had nonspecific
matches with genomic sequences of other common inhab-
itants of the vaginal cavity. BioEdit sequence alignment
editor (version 7.0) software was used to align the primers
with gene sequences to identify the most variable re-
gions (highest entropic regions) and to find new regions
for designing specific primers. GPD was used again to
examine the new primer sequences (Tm, ΔTm, GC%, self-
complementarity, repetitive sequences and Gibbs free en-
ergy). WinOligo, a specialised component of the GPD
software, was used for calculating bimolecular secondary
structures, including primer-primer interactions (hairpins,
homodimers or heterodimers), that might affect the yield
or the success of amplification reactions.
The designed primer set is a combination of four pri-
mer pairs that amplify species specific 16S rDNA target
regions of C. trachomatis (402 bp), N. gonorrhoeae (694 bp),
M. hominis (604 bp) and U. urealyticum (898 bp) from
genomic DNA. The amplicon sizes were selected during
the primer design to allow for co-amplification and appro-
priate separation on a 1.8% agarose gel by electrophoresis
to facilitate the unambiguous identification of the PCR
products by size.
PCR method
Single-locus PCR reactions were performed and stan-
dardised. PCR amplification was performed in a final
volume of 50 μL containing 100 ng of DNA template,
0.4 mM deoxynucleotide triphosphate (dNTP) mix, 1x
PCR buffer (Invitrogen™, Carlsbad, CA), 2 mM MgCl2,
0.1 μM primers, 2.5 units of Taq polymerase (Invitrogen™,
Carlsbad, CA). To prevent PCR inhibition, 0.4% bovine
serum albumin (BSA) was added. The following sequences
of the designed primers are under patent application
(MX/A/2011/011064): 16SCt-S-5’-CGA GTC GGC ATC
TAA TAC TAT-3’, 16SCt-AS-5’-AAA ACG ACA TTT
CTG CCG C-3’, 16SUu-S-5’-TAC CCT TAA GTT GGG
GAT AA-3’, 16SUu-AS-ACT ATA TTT CTA TAG CGT
CGC AA-3’, 16SNg-S-5’-GCC TCG CGG CTT GGC TA-
3’, 16SNg-AS-GGC GCA GAC GGT TAC TTA AGCAGG A-3’, 16SMh-S-5’-ACC CAT TGG AAA CAA TGG
CTA ATG CCG GAT ACG-3’ and 16SMh-AS-5’-ATA
GAC CCA GTA AGC TGC CTT CGC CT-3’. All of the
reactions were performed in a T-Gradient Thermoblock
PCR System (Biometra, Goettingen, Germany). The cyc-
ling conditions to amplify all of the individual loci (s-PCR)
consisted of an initial denaturation at 94°C for 5 min,
30 cycles of melting at 94°C for 1 min, annealing at 58°C
for 30 s, and elongation at 72°C for 1 min and a final ex-
tension at 72°C for 5 min. Primers for each locus were
added in sequential amplifications until qx-PCR was
achieved; each locus was added individually because com-
bining the primers in various mixtures and amplifying
many loci simultaneously typically required alteration/op-
timisation of the reaction parameters [13]. A minimum of
2 replicates were performed for each reaction. To verify
the presence of the amplification products, 10 μL of each
PCR was separated by electrophoresis on a 1.8% agarose gel.
A 100-bp DNA molecular marker was included in some of
the electrophoresis runs (Invitrogen™, Carlsbad, CA). The
remaining 40 μL of the amplification reaction was frozen for
later use. The products of s- and qx-PCR reactions of each
target gene were authenticated via DNA sequencing on an
ABI-PRISMTM 310 (Applied Biosystems, Foster City, CA)
using the manufacturer’s recommendations.
Generation of PCR amplification controls
After all of the amplicons were obtained, they were cloned
into a pJET1.2/blunt vector using the CloneJET™ PCR
Cloning Kit (Fermentas Life Sciences, Dharmacon, Inc.),
and Escherichia coli DH5α competent cells were trans-
formed to produce sufficient positive amplification con-
trols. Plasmid DNA from characterised transformants
was purified using CHROMA SPIN™ columns (Clontech,
Mountain View, CA) and was used as a positive control in
all of the PCR assays. Equimolar concentrations of these
amplicons were mixed and used as molecular weight
markers.
In vitro standardisation
The analytical specificity was tested in two steps. In the
first step, suspensions of S. agalactiae, L. acidophilus, G.
vaginalis and S. saprophyticus adjusted to 0.5 McFarland
Nephelometer standard, which is equal to 1.5 × 108
colony-forming units (CFU)/mL, were prepared. Gen-
omic DNA was extracted using the High Pure PCR
Template Preparation Kit (Roche, Mannheim, Germany),
and s- and qx-PCR were performed. In the second step,
adjusted suspensions were added to negative cervical
samples, which were transported and maintained in 2-
sucrose-phosphate (2SP) medium. Metagenomic DNA
was extracted (High Pure PCR Template Preparation
Kit), and s- and qx-PCR were performed to determine
the analytical specificity of a clinical sample. In addition,
Figure 1 Representative images of the standardisation process
for the detection of C. trachomatis, N. gonorrhoeae, M. hominis
and U. urealyticum by 16S rDNA gene amplification. Lanes MWM:
100-bp marker (Invitrogen™, Carlsbad, CA). The sizes (bp) are indicated
on the left. The PCR products were electrophoresed on a 1.8% (wt/vol)
agarose gel, stained with ethidium bromide and photographed under
UV light. A. Lanes 1-4: Single PCR detection of M. hominis, C. trachomatis,
N. gonorrhoeae and U. urealyticum. B. Lanes 1-2: Duplex PCR for the
simultaneous detection of M. hominis and N. gonorrhoeae; lane 3:
negative control (no template). C. Lanes 1-6: Triplex PCR for the
simultaneous detection of M. hominis, N. gonorrhoeae and U. urealyticum;
lane 7: negative control. D. Lanes 1-4: Quadruplex PCR for the
simultaneous detection of M. hominis, N. gonorrhoeae, U. urealyticum
and C. trachomatis; lane 5: negative control. Panels B, C and D also
show the effects of the target DNA concentration on the multiplex
amplifications; the best yield is shown in lanes 2, 6 and 4 using 100 ng
of DNA template.
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tion reactions was validated by re-amplification with the
addition of plasmid DNA from the four characterised
transformants as positive controls. Two replicates were
performed for each reaction, and the results were
consistent.
Genomic DNA from C. trachomatis, N. gonorrhoeae,
M. hominis and U. urealyticum was diluted in 10-fold
serial dilutions, and s- and qx-PCR were performed to de-
termine the limits of detection. Two replicates were per-
formed for each reaction, and the results were consistent.
Results
Primer design
Conserved genes were selected as the target genes, and
suitable primers were designed to detect four cervicitis-
related bacteria. The following general requirements for
design were considered: the primers have similar Tm
values; the primers would not form hairpins, homodi-
mers or heterodimers or have repetitive sequences; and
the target fragment gap should exceed 30 bp to meet the
resolution requirements for agarose gel electrophoresis.
Using GPD and its WinOligo tool, highly specific and ef-
ficient primers were generated. These primers were de-
signed with similar physical characteristics to allow for
simultaneous amplification under the same conditions
in single or multiplexed reactions. The lengths of the
primers ranged from 17 to 33 bp, and their melting tem-
peratures were between 68 and 77°C. These characteristics
are important because longer primers allowed the reac-
tion to be performed at a higher annealing temperature
and yielded fewer nonspecific products. No undesirable
primer-primer interactions or repetitive sequences were
detected. The expected amplicon sizes ranged from 402 to
989 bp. A key step in creating the primers was finding the
more variable (highly entropic) regions inside of each of
the 16S rDNA sequences and using these areas as species-
specific regions.
In vitro standardisation
The optimisation process was first performed using each
pair of primers in a separate amplification reaction (sin-
gle), and annealing temperatures ranging from 56°C to
70°C were tested. The optimal temperature was 58°C
under standard concentrations of the PCR components.
The concentrations of the primers, the PCR co-adjuvant
(BSA) and the target DNA were adjusted. Amplicons of
the expected size were obtained from each of the four bac-
terial gene fragments. The banding patterns from the gel
analysis are shown in Figure 1A. Multiplexed reactions
were performed individually in an empirically chosen
order until quadruplex amplification was achieved. In this
phase, no parameters or cycling conditions were re-
adjusted. The target DNA concentrations were adjusted to
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of the target DNA concentration on the multiplex amplifi-
cations; the best yield is shown in lanes 2, 6 and 4, respect-
ively, using 100 ng of target DNA.
To evaluate the specificity of the multiplex assay, a panel
of 5 well-characterised strains were employed in the test
(S. agalactiae, S. saprophyticus, L. acidophilus, G. vaginalis
and N. gonorrhoeae). The amplification results using the
multiplex assay are shown in Table 1. The primers yielded
a PCR product only when N. gonorrhoeae was present, as
was expected. The primers did not amplify any product
from a non-STI species (Table 1).
The detection limit for each primer set in the multiplex
format was also determined. To determine the limits,
10-fold serial dilutions of known amounts of C. trachoma-
tis, N. gonorrhoeae, M. hominis and U. urealyticum DNA
were tested in triplicate using the multiplex format. The
detection limits for the C. trachomatis, N. gonorrhoeae, M.
hominis and U. urealyticum primer sets were 5.12 × 105,
3.9 × 103, 61.19 × 106 and 6.37 × 105 copies of a DNA tem-
plate, respectively.
Discussion
The ribosomal 16S gene is a suitable molecular target
for bacterial classification because this gene is universal
among bacteria and is conserved, although it has sufficient
variation (nine hypervariable regions) to discriminate
between the majority of taxa (species-specific sequences).
One PCR primer pair could target the 16S rRNA gene from









N. gonorrhoeae Yes Yes + +
G. vaginalis Yes Yes - -
L. acidophilus Yes Yes - -
None Yes Yes - -
Mixb Yes Yes - -
S. agalactiae Yes No - -
N. gonorrhoeae Yes No + +
S. saprophyticus Yes No - -
None Yes No - -
Mixb Yes No - -
+ = presence of amplicon.
- = no amplicon was visualised on agarose gel.
aThe negativity of the samples was demonstrated by the detection of
cervicovaginal pathogens using culture, Mycoplasma IST 2 – API galleries
(bioMérieux, France) and/or PCR (data not shown).
bThe mixes include G. vaginalis, L. acidophilus, S. agalactiae and
S. saprophyticus.
2SP: 2-sucrose-phosphate transport medium.of these characteristics, a bioinformatics study was per-
formed to develop highly specific and efficient primers
for the in-house m-PCR detection of C. trachomatis,
N. gonorrhoeae, M. hominis and U. urealyticum.
The m-PCR technique could be used as a differential
method to determine whether an STI or cervicitis is
caused by one of the previously mentioned bacteria, and
this technique could be a valuable tool for reducing the
time required to make a diagnosis and initiate treatment.
Because asymptomatic infections have been described in
the literature, simple, practical and inexpensive methods
that improve the diagnoses of these bacterial infections
are necessary. These methods could be used to monitor
the prevalence of these bacteria through free routine tests,
which could be implemented in a surveillance project to
prevent further transmission of the disease [15,16].
Traditionally, testing for C. trachomatis and N. gonor-
rhoeae is performed on cervical swabs that are sent for
culture, phenotypic or immunological detection [7].
These tests are often not performed immediately, and it
could take more than two days for the results to become
available. Although several commercial tests (NAATs) are
an option for C. trachomatis and N. gonorrhoeae detec-
tion, these tests are usually more expensive and are not
readily available in some labs because the appropriate in-
frastructure is required [6]. These issues are major deter-
rents to using these kits to implement the large-scale
screening programmes that should be conducted in low-
income countries. Additionally, because of the high risk of
sequelae from untreated C. trachomatis or N. gonorrhoeae,
physicians have been told to practice symptom manage-
ment and empirically treat patients who are suspected of
having active C. trachomatis or N. gonorrhoeae infection.
Otherwise, patients might not return for their lab results
and would not wait 2 or 3 days to begin treatment. The
availability of a test such as the one described herein (in-
house m-PCR), which provides results within 3 or 4 hours
and allows for immediate treatment, is relevant because
this test reduces the risk of potential onward transmission
and sequelae. Because symptom management misses pa-
tients with mixed venereal diseases and asymptomatic
patients, the NAATs as a qx-PCR approach are highly
needed [6,17,18].
Although the roles of M. hominis and U. urealyticum
as aetiological agents of cervicitis have yet to be clarified,
their presence in the female reproductive tract has been
correlated with adverse pregnancy outcomes and adverse
consequences to newborn babies. Therefore, it is import-
ant to determine the relative frequencies of these agents
in different populations [1] and their co-prevalence with
clinical entities such as vaginitis, bacterial vaginosis and
cervicitis.
M-PCR is a rapid tool that allows for the simultaneous
amplification of more than one sequence of target DNA
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the best of our knowledge, this study is the first report
of in-house qx-PCR for this specific combination of etio-
logical agents. In addition, these primers could be used
to amplify one to all four of the different targets, making
this m-PCR a flexible technique to use with several types
of clinical samples. For example, this method could be
used for single or simultaneous detection in the diag-
nosis of the causes of trachoma (C. trachomatis), atypical
pneumonia (C. trachomatis, U. urealyticum) or non-
gonococcal urethritis (C. trachomatis, M. hominis and
U. urealyticum).
The analytical specificity of PCR depends on the
primers used, and the analytical sensitivity depends on
the presence of inhibitory substances in the specimens
[18]. The specificity of the primer combinations was
demonstrated by the negative PCR results obtained with
all of the non-STI reference strains, and the addition of
BSA in the PCR reaction was a good strategy to minim-
ise the effect of inhibitory substances in cervical speci-
mens because there was no amplification in the PCR
reactions without BSA (data not shown). However, the
clinical specificity and clinical sensitivity of the designed
PCR technique should be evaluated in a statistically sig-
nificant sample.
Recently, several researchers used in-house or com-
mercial PCR assays to identify STI bacteria by detecting
the 16S rDNA gene or other genes in s-PCR or m-PCR.
Early work by Patel et al. [19] reported the prevalence of
Chlamydia infection among women in India, which was
analysed via in-house s-PCR designed to amplify the
gyrA gene of C. trachomatis. Corbeto et al. [20] deter-
mined the prevalence of C. trachomatis infection using a
commercial real-time PCR method in Catalonia, Spain.
In contrast to those studies, the qx-PCR technique de-
scribed in this study requires a single reaction to detect
four bacterial genes related to cervicitis. Other authors
have reported a simple design that involved standardis-
ing five s-PCR techniques to specifically investigate the
relative frequencies of C. trachomatis and genital myco-
plasmas in Brazil. These s-PCR techniques are capable
of amplifying the target sequence on a cryptic plasmid of
C. trachomatis, the cppB gene of N. gonorrhoeae, the
major adhesion protein gene of Mycoplasma genitalium
and the urease gene of U. urealyticum in five different
reactions [1], whereas the qx-PCR technique described
here could be used for the simultaneous detection of
these species.
Perhaps the most complex m-PCR technique was
described by McKechnie et al. [21]. These authors re-
ported the simultaneous identification of 14 genital
microorganisms, including C. trachomatis, N. gonorrhoeae,
M. hominis and U. urealyticum, in the urine of human
males using an m-PCR-based reverse line blot assay(m-PCR/RLB). The set of targets examined by these
authors is better suited to the detection of important
aetiological agents of male urethritis [21]. The authors
concluded that their m-PCR/RLB technique could be
used for routine diagnosis and epidemiological stud-
ies because it is more practical and less expensive than
microarray technology. The qx-PCR technique de-
scribed here could represent a more widely applicable
method for analysing samples because it is cheaper,
easier to perform and comparable in sensitivity to m-
PCR/RLB.
De Haro et al. [9] used an s-PCR (t-PCR) technique to
amplify the ompA gene of C. trachomatis in 152 endo-
cervical samples from infertile women, and Hernández-
Martínez et al. [10] use two s-PCR to detect C. tracho-
matis or N. gonorrhoeae and phenotypic kits to identify
genital mycoplasmas in 105 endocervical samples from
the general population. Although the De Haro and
Hernández-Martínez studies were similar in design, the
latter study characterised a wider range of bacteria. Both
studies attempted to determine the relative frequencies of
various genital infectious agents and to determine which
species are the most plentiful in different populations. In
the context of these previous studies, the qx-PCR tech-
nique described here could be an improved new method.
C. trachomatis, M. hominis and U. urealyticum are wide-
spread in females who were not considered at-risk, and
C. trachomatis infections were diagnosed in asymptom-
atic patients [10]. These results increase our interest
in generating a rapid, inexpensive and practical new
methodology that is applicable to a larger number of sam-
ples in a short time and is not dependent on sophisti-
cated technology.
The qx-PCR system reported in this study reduces
analysis time and promises to be a tool that provides
more accurate risk assessments and could be used for
monitoring the pathogenic strains of the most frequently
identified cervicitis agents. The qx-PCR method exhib-
ited acceptable specificity and sensitivity even when the
clinical samples were suspended in a transport medium
such as 2SP. However, these results should be confirmed
with a larger set of samples in a future study to evaluate
the clinical specificity and sensitivity.
Conclusions
We developed and evaluated a qx-PCR assay for the rapid
detection of cervicitis-related bacteria. Although sophisti-
cated methodologies have been designed, using endpoint
PCR to detect 16S rDNA genes remains a good approach
for estimating the incidence and prevalence of several bac-
teria and for monitoring infections. The qx-PCR tech-
nique would be valuable as a simple tool to screen for the
presence of these bacteria because the specific combin-
ation of genes employed facilitates the identification of
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laboratories.
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